Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the breast cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of pharmacy and medical benefits.
Subscribe to:
Post Comments (Atom)
< + > Enabling Stroke Survivors – Life Sciences Today Podcast Episode 80
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Jennifer Ernst, C...
No comments:
Post a Comment